Table 2.

Hazard ratios for survival data according to MDM2 genotypes. T/G + G/G (Reference: HR = 1.0) vs. T/T

				DFS				OS
Histology	Pathological stage		N	Event	HR	95% CI	P	Event	HR	95% CI	P
All	Stage I‐III	a	453	153	1.15	078–1.69	0.48	118	1.01	0.64–1.58	0981
AC		b	328	99	1.93	1.21–3.07	0.01	73	2.05	1.19–3.51	0.01
SQ		b	107	54	0.71	0.32–1.53	0.38	45	0.50	0.20–1.28	0.15
AC	Stage I	b	246	47	2.11	1.13–3.95	0.02	35	3.00	1.44–6.24	0.003
	Stage II, III	b	82	52	1.78	0.87–3.67	0.12	38	1.33	0.54–3.30	0.54
SQ	Stage I	b	63	24	0.75	0.21–2.67	0.66	18	0.34	0.04–2.67	0.30
	Stage II, III	b	44	30	0.65	0.22–1.92	0.44	27	0.65	0.19–2.17	0.48

P < 0.05 are shown in bold. DFS, disease‐free survival; OS, overall survival; AC, adenocarcinoma; SQ, squamous cell carcinoma.

^aHazard ratio adjusted for age, sex, stage, histology, treatment (chemotherapy after tumor recurrence), and smoking status.

^bHazard ratio adjusted for age, sex, treatment (chemotherapy after tumor recurrence), and smoking status.